Five-year overall survival of metastatic renal cell carcinoma patients treated with everolimus after progressionon bevacizumab: a prospective multicenter study CRAD001LRU02T

Onkourologiâ

S. A. Varlamov¹  I. S. Varlamov¹  I. V. Tsimafeyeu²  L. V. Manzuk³  A. V. Snegovoy³  L. I. Gurina⁴  S. Z. Safina⁵ 

[1] Altai Regional Oncology Dispensary;Kidney Cancer Research Bureau;N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia;Primorsky Regional Oncology Center;Republican Clinical Oncology Dispensary, Ministry of Health of the Republic of Tatarstan;

关键词: everolimus;    bevacizumab;    interferon;    metastatic renal cell carcinoma;    5-year overall survival;   

DOI  :  10.17650/1726-9776-2017-13-4-40-44

来源: DOAJ

【 摘 要 】

Background. In a CRAD001LRU02T study of everolimus for metastatic renal cell carcinoma patients previously treated with bevacizumab ±  interferon, median overall survival (OS) was 17.4 months (95 % confidence interval 13.5–21.3 month).Objective of final analysis was to evaluate 5-year OS and long-term toxicity in this study.Materials and methods. Survival data were collected from 37 patients with bevacizumab-refractory metastatic renal cell carcinoma who received everolimus in a completed prospective multicenter study. Patients were predominantly male, 89 % had ECOG performance status of 0/1, 51 % received previous bevacizumab in combination with interferon, and 38/62% had MSKCC favorable/intermediate risk disease.Results. The 5-year survival rate was 16.2% (95 % confidence interval 14.1–18.3 %), with a median follow-up of 5 years. The 1-, and 3-year OS rates were 81.0 and 43.0 %, respectively. The median duration of second-line of everolimus was 315 (range 61–569) days. 11 (29.7 %) patients received third-line therapy with a median duration of 3.6 months. Confirmed objective tumor responses were seen in 5 (14.0 %) patients. 70.0 % (n = 26) patients had a stable disease. 1 (2.7 %) patient achieved complete response after 4 years of therapy. One (2.7 %) patient  discontinued everolimus therapy on their own accord due to relapse of systemic lupus erythematosus and one (2.7 %)  patient had 14-days interruption of an everolimus therapy due to grade 3 hyperglycemia. No grade 4 treatment-related toxicity was found.Conclusions. Everolimus provided an estimated 5-year survival rate of 16.2 % for bevacizumab-resistant metastatic renal cell carcinoma. Prolonged everolimus was not associated with new types or increased severity of adverse events.

【 授权许可】

Unknown